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ABSTRACT Prevention of serious infections in pregnant mothers, newborns, and
young infants through immunization during pregnancy and in early life has the poten-
tial to further reduce maternal and neonatal morbidity and mortality worldwide. In the
past decade, research in this ﬁeld has advanced substantially, from the understanding of
the biology and immunology of pregnancy and early life, to the active development of
several candidate vaccines, for which challenges and opportunities for global implemen-
tation are under consideration. Experts from academia, industry, regulatory and funding
agencies, public health, and international organizations met in Brussels (Belgium) from
10 to 12 September 2017, at the 4th International Neonatal and Maternal Immunization
Symposium (INMIS), to review the most relevant advances in maternal and neonatal im-
munization. The overarching focus of the conference was to identify the path forward to
achieve integration of maternal and early life immunization strategies for the successful
implementation of vaccines in antenatal care and pediatric programs for reduction of
maternal and infant mortality worldwide.
IMPORTANCE This report provides an overview of the proceedings of the 4th Inter-
national Maternal and Neonatal Immunization Symposium, where presentations fo-
cused on the state-of-the-art research on the development and implementation of
vaccines given during pregnancy for the protection of mothers and infants.
KEYWORDS maternal immunization, neonatal, infant, vaccines in pregnancy,
vaccination, immunology, integration, implementation
The integration of infant and maternal immunization: a global challenge.
Global maternal and infant mortality remains unacceptably high in the 21st century.
Despite a 44% reduction since 1990, the global maternal mortality ratio was estimated
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to be 216 (207 to 249) per 100,000 live births in 2015, with 303,000 (291,000 to 349,000)
maternal deaths (830 per day), mostly associated with pregnancy and childbirth
complications, 99% occurring in the developing world (1). Similarly, 4.9 million children
under 5 years of age died in 2015 (nearly 16,000 every day), with neonatal mortality
accounting for approximately 45% of all deaths (2). The World Health Organization has
therefore included in their 2030 Sustainable Development Goal (SDG) targets the goal
to reduce the global maternal mortality ratio to 70 per 100,000 live births and end
preventable deaths of newborns and children under 5 years of age, aiming for all
countries to reduce neonatal mortality to 12 per 1,000 live births and under-5
mortality to 25 per 1,000 live births (2). To achieve these targets, interventions
addressing the prominent causes of mortality in these target groups are required.
Expansion, enhancement, and integration of maternal and early life immunization, key
public health interventions, have the potential to address some of these goals (3).
Pregnant women and infants have a high risk of exposure to infectious disease, and
vaccines administered during pregnancy and/or early life offer the potential to protect,
depending on the vaccine, mothers against infection-related morbidity and mortality
and infants against infection-related morbidity, neonatal death, stillbirth, and preterm
birth. The feasibility of maternal immunization is supported by the success of the
longstanding Maternal Neonatal Tetanus Elimination (MNTE) program. Given the grow-
ing number of vaccines recommended for use during pregnancy (i.e., inﬂuenza and
pertussis), and of new maternal vaccines in development (i.e., respiratory syncytial virus
[RSV] and group B streptococcus [GBS]), it is critical to understand the challenges and
opportunities to implement maternal immunization in areas where vulnerable popu-
lations would beneﬁt the most, including low- and middle-income countries (LMIC),
leveraging existing antenatal care (ANC) programs. In 2015, experts at a Bill & Melinda
Gates Foundation (BMGF)-convened meeting on maternal immunization in resource-
limited settings agreed that maternal immunization must be integrated within the ANC
platform (4). This approach is supported by the Strategic Advisory Group of Experts on
Immunization (SAGE), who have advised the World Health Organization (WHO) to
generate generalizable data on the best ways to integrate maternal immunization into
routine antenatal care in low-resource settings. Several global projects are addressing
this mandate and identifying opportunities and challenges for the introduction of new
vaccines for maternal immunization: the Maternal Inﬂuenza Immunization project,
which provides guidelines for the implementation of inﬂuenza vaccination in pregnant
women in LMIC, and the Maternal Immunization in Antenatal Care Situational Analysis
(MIACSA), which aims to evaluate tetanus maternal vaccine delivery via existing ANC
programs and identify opportunities and challenges for the introduction of new
vaccines for maternal immunization (5). Vaccines speciﬁcally being developed for
maternal immunization include a vaccine against GBS, the leading etiologic agent of
neonatal sepsis and neonatal meningitis plus substantial maternal morbidity/mortality
during pregnancy and postpartum, and an RSV vaccine in order to prevent the
substantial morbidity and mortality caused by RSV in young infants. Similarly, PATH’s
Advancing Maternal Immunization (AMI) collaboration, in collaboration with WHO,
evaluates RSV implementation as a maternal vaccine, particularly in LMIC (https://sites
.path.org/cvia/our-disease-targets/respiratory-syncytial-virus/advancing-maternal
-immunization-ami/).
During 2015 and 2016, the WHO Product Development for Vaccines Advisory
Committee (PDVAC) identiﬁed as a priority the development of GBS vaccines suitable
for maternal immunization in pregnancy and use in LMIC. In response, WHO developed
a GBS Preferred Product Characteristics (PPC) guideline and a Vaccine Development
Technology Roadmap to focus on activities leading to development, testing, licensure,
and global availability of GBS vaccines. These documents are available at http://www
.who.int/immunization/research/development/ppc_groupb_strepvaccines/en/. In April
2016, SAGE acknowledged the high importance of RSV vaccine development to prevent
pediatric morbidity and mortality. Since then, an RSV vaccine has been advanced to
phase 3 clinical trials in pregnant women. To further inform vaccine development,
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licensure, and prequaliﬁcation, WHO has developed guidance on RSV vaccine efﬁcacy
trial design (prevention of acute disease) with focus on LMIC, an RSV vaccine technol-
ogy roadmap, and an RSV vaccine Preferred Product Characteristics (PPC) document to
guide vaccine development and evaluation. These can be found at http://www.who
.int/immunization/research/development/ppc_rsv_vaccines/en/. Regulatory and physi-
cal standards for RSV vaccines, appraisal of data relevant to RSV vaccination policies,
and vaccine use and guidance on long-term vaccine evaluation are included in these
documents.
The 4th International Neonatal and Maternal Immunization Symposium (INMIS)
convened experts from academia, industry, regulatory and funding agencies, public
health, and international organizations in Brussels (Belgium) from 10 to 12 September
2017, to review the most relevant advances in maternal and neonatal immunization.
The overarching focus of the conference was to identify the path forward to achieve
integration of maternal and early life immunization strategies for the successful imple-
mentation of vaccines in antenatal care and the harmonization of vaccination and
maternal and neonatal health care programs to impact maternal and infant mortality
worldwide. Nearly 300 participants attended the two-and-a-half-day meeting that
included 16 invited expert presentations, 25 oral presentations from submitted ab-
stracts, 30 poster presentations, and 2 expert panel discussions. The meeting sessions
were organized to begin on day 1 with the general topic of immunology, including
understanding antibodies and their transfer from mother to infant, neonatal immuni-
zation, and heterologous immunity. The second day was dedicated to providing
updates on vaccines under development for maternal and neonatal immunization,
addressing also safety, awareness, and perception issues. Finally, the third day focused
on implementation aspects of maternal and neonatal immunization worldwide and
future directions, including new and future targets of maternal and neonatal immuni-
zation.
Immunology. (i) Antibodies and their transfer. As an introduction to the devel-
opment of new vaccines, Margaret Ackerman (Dartmouth College, USA) discussed how
vaccine design can be informed by systems serology, an approach she pursues in
collaboration with Galit Alter (Ragon Institute, Cambridge, MA, USA). Using HIV infec-
tion and HIV vaccines as examples, Dr. Ackerman illustrated how machine-learning
tools can be employed to learn the principles of an effective antibody (Ab) response in
human subjects. Speciﬁcity and neutralizing activity of antibodies (Abs) are dependent
on their Fab (fragment antigen binding) domain, whereas the Fc (fragment crystalliz-
ing) domain mediates effector functions through their interactions with innate immune
cells and complement. The importance of these interactions is illustrated by the
reduced efﬁcacy of HIV broadly neutralizing antibodies with mutations preventing their
interaction with Fc receptors (6). The effector functions that can be mediated by IgG Fc
domain are diversiﬁed by the different IgG subclasses and by posttranslational modi-
ﬁcations primarily involving glycosylation. The importance of Fc glycosylation is illus-
trated by the impact of maternal antiplatelet IgG fucosylation on the severity of fetal
thrombocytopenia. To gain insight into the rules governing vaccine efﬁcacy, Ab re-
sponses to two HIV vaccine formulations based on the same antigens (VAX003 versus
Rv144) were compared. A large range of features was assessed to broadly characterize
Abs and identify correlates of protection. Structural Ab features could be linked to
receptor binding and functional properties, and these could be correlated with vaccine
efﬁcacy. These observations support the notion that systems serology could inform
vaccine design for diverse populations, including pregnant women and infants.
Dana Wolf (Hadassah University Hospital, Israel) discussed how congenital infections
provide insight in placental biology and transfer of maternal immunity. The placenta
plays a central role in maternal tolerance of the fetus and actively transports maternal
IgG via the neonatal Fc receptor expressed by syncytiotrophoblasts. The placenta is also
an innate immune barrier against pathogens. Syncytiotrophoblasts are known to be
resistant to infection with multiple pathogens. It is thought that fetal infection may
Meeting Highlights
November/December 2018 Volume 3 Issue 6 e00221-18 msphere.asm.org 3
involve the transplacental transport of complexes formed by pathogens and maternal
antibodies. On the other hand, infection of the decidua, forming the maternal compo-
nent of the placenta, is likely to be the initiation of pathogen transmission to the fetus.
Dr Wolf presented the development of ex vivo models of infection of decidua cultures
allowing the characterization of pathogen spread and innate immune responses. These
models demonstrated that cytomegalovirus (CMV) spreads from cell to cell whereas
Zika virus (ZIKV) spreads via the extracellular space. Gene expression analyses revealed
that CMV and ZIKV induce distinct placental responses that may underlie distinct
mechanisms of viral control and tissue damage. In-depth analysis of gene expression
indicated that the intrinsic cellular restriction factor APOBEC3A (A3A) may be an
important innate mechanism of CMV control at the placental level (7). This work should
help the development of interventions protecting placental functions and preventing
pathogen transmission following maternal infections.
Thao Mai Phuong Tran (University of Hasselt, Belgium) discussed the mathematical
modeling of maternal antibody titers in infants, after maternal immunization in Belgium
and Vietnam with different brands of pertussis-containing vaccines. Different maternal
antibody kinetics but similar half-lives were noted in young infants in both countries
(concentrations at birth were lower in infants in Vietnam than in infants in Belgium).
Future research will assess the impact of the timing of maternal vaccination at different
stages of gestation on antibody concentrations in infants at birth, to further reﬁne these
models. Mustapha Jaiteh (Medical Research Council Unit, The Gambia [MRCG], at the
London School of Tropical Medicine [LSHTM]) presented preliminary results suggesting
an impact of maternal vaccination with 13-valent pneumococcal conjugate vaccine on
the presence of vaccine antigen-speciﬁc memory B cells in colostrum and a potential
mechanism underlying neonatal protection via maternal immunization through breast
milk antibodies.
(ii) Neonatal immunization. Despite challenges inherent to vaccine development
in the very young, there is a robust rationale for continued vaccine development for
this population, including (a) birth is the most reliable point of health care contact and
therefore neonatal vaccines achieve high population penetration; (b) neonatal immu-
nization is a logical approach to protect preterm infants, who represent11% of all live
births and are often born prior to transfer of maternal antibodies (MatAbs) (such that
maternal immunization may not be protective); and (c) growing evidence that the
heterologous beneﬁts of certain vaccines such as BCG may be greatest in early life (8).
Beate Kampmann (Imperial College London and MRCG at LSHTM, The Gambia)
challenged the view that newborns do not respond well to vaccines and emphasized
the importance of considering differences between newborns and between vaccines.
Immune ontogeny in early life shapes innate and adaptive responses and is inﬂuenced
by maternal cofactors (9). Immune plasticity is required to integrate genetic and
environmental factors and to adapt to the ex utero environment. Immune components
central to vaccine responses, including antigen-presenting cells, B cells, and T cells,
function differently at birth than later in life. Maternal cofactors inﬂuencing immune
ontogeny and immune responses in early life include chronic maternal infections,
nutrition, and the microbiome and the levels and speciﬁcity of maternally acquired
antibodies. Vaccines currently given at birth provide strong evidence that protective
immunity can be induced by vaccination and can also inform on the potential of
neonates to develop speciﬁc immune responses and on the impact of cofactors. Studies
of BCG immunization have demonstrated that Th1 responses can be induced at birth
and that BCG vaccination can have heterologous effects on the response to other
vaccines and on overall infant mortality (8, 10). Studies of hepatitis B and oral polio
immunization at birth indicated that priming of memory B cells can be achieved in early
life, allowing the option to immunize infants at birth. An ideal vaccine to be adminis-
tered to neonates would induce rapid immune response even in the presence of
MatAbs and would have an optimal safety proﬁle (11).
Nicholas Wood (University of Sydney, Australia) discussed the role of neonatal
immunization for protection against bacterial pathogens, including pertussis, Haemo-
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philus inﬂuenzae type b (Hib), and pneumococcus. The majority of deaths due to
whooping cough occur in the ﬁrst two months of life. Pertussis vaccination in early life
has resulted in variable outcomes. Historical studies suggested that immune tolerance
may result from neonatal pertussis immunization with whole-cell vaccines. More recent
studies showed that acellular pertussis vaccination at birth increases the response to
the second dose of vaccine at 2 months of life (a priming role). Some studies showed
reduced responses to vaccines concomitantly administered with the second pertussis
vaccine dose. Another limitation of pertussis immunization at birth may be the induc-
tion of Th2-polarized cellular immune responses. Neonatal pertussis immunization may
be indicated in babies born to mothers who have low Ab levels, reduced response to
pertussis vaccine, or reduced transfer of MatAbs. From a public health point of view, the
feasibility of such indications can be questioned. Several studies of neonatal Hib
immunization showed good safety and priming of booster responses with polyribosyl-
ribitol phosphate-diphtheria CRM 197 protein (PRP-CRM) and PRP-tetanus protein
(PRP-T) vaccines but reduced booster responses to a PRP-outer membrane protein
(PRP-OMP) vaccine. Studies of neonatal immunization with pneumococcal conjugate
vaccine showed good safety and early induction of Abs, but their impact on invasive
disease or carriage has not yet been demonstrated.
Merryn Voysey (University of Oxford, United Kingdom) discussed prevalence and
decay of MatAbs from different pneumococcal and meningococcal vaccine trials and
showed differences between serotypes, serogroups, and countries (12). The presence of
MatAbs results in interference with active infant immunization. These data are useful for
modeling the impact of programs that utilize a combination of maternal and infant
vaccination strategies. Ofer Levy (Precision Vaccines Program, Boston Children’s Hos-
pital and Harvard Medical School, USA) presented preliminary in vitro studies employ-
ing human whole-blood assays raising the possibility that BCG formulation heteroge-
neity may contribute to variability in clinical beneﬁt, including “off-target” heterologous
protection, highlighting the need to further standardize and compare different BCG
vaccines to optimize beneﬁt. Data presented by Ed Clarke (MRCG at LSHTM, The
Gambia) showed that vaccine-speciﬁc memory B cell responses to pneumococcus
antigens can be detected in mothers and infants after maternal immunization with
13-valent pneumococcal vaccine. Gaelle Noel (University of Maryland School of Medi-
cine, USA) presented data demonstrating that breast milk enhances the intestinal
mucosal barrier in a pediatric human enteroid model. John Ojal’s (KEMRI-Wellcome
Trust Research Program) data indicated that naturally acquired MatAbs against pneu-
mococcal proteins protect infants from carriage whereas vaccine-induced antipolysac-
charide Abs may require concentrations higher than those induced by natural immu-
nity to be effective (13).
(iii) Heterologous immunity. Mihai Netea (Radboud University, The Netherlands)
reviewed the concept of innate immune memory and heterologous effects of vaccines.
He highlighted that upon introduction of BCG vaccine in Sweden in 1927 to 1931,
infant mortality dropped from 11% to 4% in a manner that could not be accounted for
solely by prevention of tuberculosis. Subsequently, randomized studies of low-birth-
weight newborns in Guinea Bissau demonstrated that newborns who received BCG at
birth versus at 2 months had an 50% reduction of mortality. Several investigators
have hypothesized that the mechanisms underlying such rapid BCG effects may relate
to innate immunity. From an evolutionary perspective, it may not seem logical that
vertebrates, representing only 5% of all known organisms, would rely on only adaptive
responses for immunological memory. Moreover, broad systemic acquired resistance to
pathogens is well described in plants and can be transmitted to the next generations
via epigenetic mechanisms. Such innate memory also exists in mammals but has been
less well studied. For example, in mice lacking T and B lymphocytes, myeloid cells
provide protection following vaccination with Candida. This protection also involves
epigenetic mechanisms. Key histone modiﬁcations increasing access to chromatin are
detected in primed monocytes, and blocking these modiﬁcations inhibits cell priming.
These epigenetic modiﬁcations are related to metabolic changes, including changes in
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the Krebs cycle, also demonstrable in human adults following BCG vaccination. Their
relevance for antimicrobial defense is supported by recent data indicating decreased
viral replication in subjects who received BCG before yellow fever vaccination (14).
Overall, it is evident that innate immune responses can change in an adaptive manner
after infection or vaccination.
Carlo Pietrasanta (Boston Children’s Hospital and Harvard Medical School, USA)
reported that certain combinations of Stimulator of Interferon Genes (STING) and
Toll-like receptor (TLR) agonists act in synergy to activate Th1-polarizing responses from
human neonatal antigen-presenting cells, suggesting that STING agonists, alone or
combined with alum and/or TLR agonists, may be candidate adjuvants for early life
immunization (15). Selena Alonso (Barcelona Institute for Global Health, Spain) dis-
cussed the impact of maternal infections on infant responses to vaccines. She pre-
sented results of a study conducted in Mozambique indicating altered immune re-
sponses to vaccine antigens (Hib, rotavirus, pertussis, and diphtheria) in infants born to
mothers infected with HIV or malaria. Unexpectedly, intrapartum prophylaxis with
meﬂoquine had a negative impact on vaccine responses. Jishnu Das (Ragon Institute,
USA) described a study conducted in Belgium and showing that HIV-exposed unin-
fected infants are at higher risk of hospitalization for infection of various etiologies than
unexposed infants. Risk of hospitalization was related to time at initiation of antiret-
roviral therapy in the pregnant women and was predicted by immune alterations
measured at birth. The risk for hospitalization was 4-fold higher when mothers initiated
therapy during pregnancy but not signiﬁcantly increased when treatment was started
before pregnancy (16).
Update on vaccines under development for maternal and neonatal immuniza-
tion. (i) RSV immunization in pregnancy. Fiona Culley (Imperial College London,
United Kingdom) reminded the audience that RSV is the leading single cause of
hospitalization of infants worldwide and a signiﬁcant cause of global deaths, especially
in LMIC. As adults can be repeatedly infected with the same RSV strain, natural
immunity may be only partially effective. Natural serum Ab is associated with protec-
tion, although nasal RSV-speciﬁc IgA may provide better correlation. The best evidence
of protection comes from the success of monoclonal antibody (MAb) to F protein. On
the other hand, the age proﬁle of RSV disease supports an association between
susceptibility and levels of MatAb. One modeling study showed that for every doubling
of Ab by a vaccine, severe disease may be reduced by 30% and protection prolonged
for an additional 50 days. Maternal immunization is an attractive option, and a number
of vaccine candidates are under development and evaluation (15, 17). Factors that are
important to consider for candidate vaccines include howmuch Ab is generated in themother,
the variability of the response, the best gestational age to vaccinate, the protection of
the mother, the placental transfer of Ab, the impact of breast feeding, the persistence
of the presence of passively acquired Abs, the possible interference with infant re-
sponse to natural infection, and the potential effect of delaying the age of infection to
later in childhood. Additional strategies to be considered include cocooning, the use of
pediatric RSV vaccines, and of extended-half-life MAb formulations.
(ii) GBS immunization in pregnancy. Group B streptococcus is a leading cause of
maternal and neonatal morbidity worldwide. Recent estimates associate GBS with at
least 409,000 (uncertainty range [UR], 144,000 to 573,000) maternal-fetal-infant cases of
disease and 147,000 (UR, 47,000 to 273,000) stillbirths and infant deaths annually. It is
anticipated that an effective vaccine could substantially reduce the burden of GBS
disease (18).
Shabir Madhi (University of Witwatersrand, South Africa) emphasized that GBS
disease is underrecognized as a global cause of deaths and disability, especially in LMIC,
in part because the current tools for measurement are suboptimal (19). Previous
estimates show the virtual absence of GBS in Southeast Asia. This observation contrasts
with the substantial maternal colonization rates in that setting. Underdetection of
invasive infections may be due to the fact that 90% of early-onset disease occurs on day
1 of life and the bulk of disease and attributable infant mortality will be unrecognized
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if cases die at home or are not investigated adequately in health care facilities due to
resource constraints. Even in high-income countries with effective use of intrapartum
antibiotics, there remains a residual burden of early-onset disease, and intrapartum
prophylaxis has had no impact on late-onset disease. Since the historical observation
that lower levels of anticapsular Ab are correlated with invasive disease, work to deﬁne
a threshold associated with protection has progressed but has been limited by the use
of different and unstandardized assays. Recent studies of conjugate vaccines have
demonstrated safety and immunogenicity with good persistence of Abs in vaccinated
mothers, with variation by preexisting natural immunity, comorbidities, and ethnicity.
Good placental transfer and Ab persistence in infants have also been observed, but
long-term persistence of MatAb may be less important for GBS than for other infections
such as RSV because the highest burden of GBS mortality is in the ﬁrst week of life, and
coverage for the ﬁrst 3 months of life through maternal vaccination is sufﬁcient to
address both early- and late-onset disease. HIV infection is an important risk factor for
infant GBS disease, and lower responses to candidate GBS vaccines have been seen in
HIV-infected than in uninfected women. Dr. Madhi referred to two recent WHO publi-
cations describing the pathway for development and preferred product characteristics
for GBS vaccines (20, 21).
Manu Chaudhary (Baylor College of Medicine, USA) shared the results of a study
conducted in the United States where GBS colonization prevalence in women from
India or of Indian descent living in the United States was comparable to that generally
in the United States but higher than in India. Further, GBS colonization prevalence was
higher in women of Indian descent who were born in the United States than in those
born in India, while isolated GBS types were reﬂective of both countries, including type
VII (prevalent in South Asia) and type IV, which is emerging in the United States (22).
(iii) Pertussis immunization in pregnancy. Kathryn Edwards (Vanderbilt University
School of Medicine, USA) gave an overview on the historical perspective, the rationale,
maternal-fetal antibody transfer, and the effectiveness and safety of maternal immu-
nization against pertussis and discussed the impact of maternal antibody (MatAb) on
infant immune responses to pertussis-containing vaccines. Evidence is robust that
maternal immunization with acellular pertussis vaccines is safe and effective in pro-
tecting neonates and young infants from disease. This is in line with the increasing
body of evidence supporting safety, immunogenicity, and protective efﬁcacy of Tdap in
pregnancy (23, 24). Studies evaluating the optimal timing of vaccination during preg-
nancy indicate that vaccination in the second or early third trimester might result in
higher neonatal Ab concentrations (25, 26). The impact of MatAbs modifying the infant
immune responses, however, is one of the remaining challenges of Tdap vaccination in
pregnancy research (27–29). Finally, there is a theoretical concern about interference of
CRM-conjugated vaccines with responses to infant vaccines—which has not been
shown in these recent studies.
Nasamon Wanlapakorn (Chulalongkorn University, Thailand) presented results from
an ongoing study in Thailand (2016 to 2018) where infants born to Tdap-vaccinated
women are randomized to either whole-cell pertussis- or acellular pertussis-containing
infant vaccines. The optimal timing of Tdap vaccination in pregnancy was calculated to
be at least 8 weeks prior to delivery; the ratio of maternal/cord vaccine-induced Abs
was higher when Tdap vaccine was offered earlier in pregnancy. Results on infant
responses were not yet available.
Thomas Rice (Imperial College London, United Kingdom) reported on the MatImms
study at Imperial College in the United Kingdom, which investigates the contributions
of emerging pertussis strains to early cellular immune responses to vaccines, using a
whole-blood stimulation assay (30). Elevated cellular immune responses in vaccinated
women suggest that vaccination in pregnancy also boosts cellular responses in women.
Strain-dependent responses were evident, and signiﬁcantly higher Ab titers were
present in the vaccinated women and persisted in their offspring until infant vaccina-
tion started. After 3 aP-containing infant vaccines, cytokine responses were again strain
dependent and differed in some cytokines in infants.
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Carolina Argondizo (Adolfo Lutz Institute, Brazil) also reported on the cellular
immune response patterns of mothers and infants, using ﬂow cytometry. Tdap in
pregnancy enhanced anti-PT cellular immune responses in women, conﬁrming boost-
ing of cellular immunity at adult age. After 3 doses of wP-containing vaccines given to
the infants, infant cellular immune responses were no different between the study
groups born to vaccinated and to unvaccinated women, despite a blunting effect of
MatAbs in infants born to vaccinated women.
In the discussion, the question was raised whether the above-mentioned studies can
capture vaccine “nonspeciﬁc” or heterologous effects of maternal immunization, re-
quiring the assessment of nonspeciﬁc features in the study design as well as larger
study populations for broader documentation of disease morbidity and mortality. In
summary, after a thorough review of the existing evidence on maternal Tdap vaccina-
tion beneﬁts and remaining knowledge gaps, study results from Thailand, Brazil, and
the United Kingdom could answer one of the remaining questions on the impact of
maternal vaccination on cellular immune responses in both the women and their
infants.
Safety, awareness, and perception of maternal and neonatal immunization.
The next session was dedicated to examine perceptions related to maternal immuni-
zation globally and how they might impact vaccine uptake and the global efforts under
way to strengthen and harmonize safety monitoring in this area.
(i) Perception of risk related to maternal and neonatal immunization: the
importance of building trust. Heidi Larson (London School of Hygiene and Tropical
Medicine, United Kingdom) opened the session and provided her insights into the
issues related to vaccine acceptance. She highlighted the universally sensitive nature of
pregnancy worldwide, irrespective of culture, and the fact that anxieties related to
many vaccines have focused on their perceived effects on fertility and reproduction.
HPV vaccines are a particular example. The fact that a health belief model incorporating
only an individual’s understanding of the risks of the disease and the acceptability of
the intervention represented an oversimpliﬁcation and that the “emotional determi-
nants of health” also needed to be included was also discussed. Dr. Larson highlighted
that trust in product (i.e., the vaccine), provider, and policy or policy maker was required
for effective vaccine delivery and that uptake was likely to be compromised if any such
component was lacking. She also drew attention to the fact that vaccines targeting
disease in newborns (e.g., pertussis) might be accepted differently from those predom-
inantly targeting maternal disease (e.g., inﬂuenza). Finally, Dr. Larson described the
efforts of the Vaccine Conﬁdence Project (http://www.vaccineconﬁdence.org/) to es-
tablish estimates regarding population views of the importance, safety, effectiveness,
and compatibility with religious beliefs and outlined the many local contextual factors
inﬂuencing such estimates.
(ii) Assessment of safety. Linda Eckert (University of Washington, Seattle, WA, USA)
described efforts to harmonize the assessment of the safety of vaccines in pregnancy,
providing her perspectives as a front-line obstetrician. She ﬁrst highlighted that safety
represents a key obstacle to maternal immunization and that the efﬁcient use of data
to study outcomes requires agreement regarding the terms and deﬁnitions being used.
Dr. Eckert described the Global Alignment of Immunization Safety Assessment in
Pregnancy, the GAIA consortium based on the Brighton Collaboration, which has
recently published 21 deﬁnitions (10 obstetric and 11 neonatal) for use in safety
reporting after maternal immunization (http://gaia-consortium.net/). The CROWN ini-
tiative, which was set up by journal editors to establish a core outcome set for reporting
obstetric and neonatal studies, was also described (http://www.crown-initiative.org/). A
set of preterm birth core outcomes has recently been published by this group, and
further outcomes are to follow. A number of other ongoing initiatives were described
before Dr. Eckert concluded that we are poised for a new era in harmonization of safety
reporting in the ﬁeld of maternal and neonatal vaccination.
Clare Cutland (University of the Witwatersrand, South Africa) provided a perspective
from LMIC on assessing the safety and efﬁcacy of maternal vaccines, considering
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immunization data collected routinely in health care facilities in South Africa, The
Gambia, Ghana, India, and Nepal. She highlighted that the collection of safety data in
clinical trials and routinely following implementation would present different chal-
lenges. Paper-based, patient-held immunization records currently in use in these
countries do not have ﬁelds for recoding of essential data, including vaccine lot
number, manufacturer, volume, and site of immunization. A lack of reliable electricity
supply and computer/tablet hardware availability in many LMIC limits electronic data
capturing. In a clinical setting in South Africa, creative solutions such as the use of
different sizes of local coins to allow evaluators to consistently measure the size of local
vaccine reactions have been utilized. In the majority of LMIC, pregnancy records are
maintained on paper cards, which are taken home by the mother postdelivery. No
system for the central storage of antenatal data is in place, hampering assessment of
background rates of maternal, fetal, and newborn adverse events and making retro-
spective studies nearly impossible. A number of steps that could be taken to enhance
safety reporting in LMIC were described to ensure that the future introduction of
vaccines where they are most needed will not be delayed.
Ousseny Zerbo (Kaiser Permanente Vaccine Study Center, USA) presented data
generated in the Kaiser Permanente site in northern California, demonstrating the
ability to conduct powerful analyses using extensive data on 145,000 deliveries. The
study conﬁrmed an absence of association between maternal inﬂuenza vaccination and
different adverse birth outcomes, including preterm birth, low birth weight, and large
and small sizes for gestational age (31).
Penda Johm (MRCG at LSHTM, The Gambia) discussed qualitative data generated in
the context of a maternal Prevenar13 vaccination trial in The Gambia. She reported that
both maternal and neonatal doses of the vaccine were perceived to be safe by study
participants, although it was apparent that there was a variable level of understanding
regarding the illnesses that the vaccine may prevent. Potential barriers to future uptake
were identiﬁed and are the focus of further studies to be undertaken in The Gambia
and Senegal, outside the sites already undertaking vaccine trials, in order to eliminate
bias.
Steve Anderson (Food and Drug Administration, United States) described the work
of the U.S. Food and Drug Administration (FDA) to develop capabilities to monitor the
safety of vaccine use during pregnancy through the sentinel Initiative of the Post-
licensure Rapid Immunization Safety Monitoring (PRISM) program (https://blogs.fda
.gov/fdavoice/index.php/tag/sentinel-initiative/), an active surveillance system that an-
alyzes information in electronic health care databases.
Implementing maternal and neonatal immunization worldwide. Philip Lambach
(WHO Initiative for Vaccine Research) provided a global perspective on the opportu-
nities and challenges for maternal immunization with a particular focus on the lessons
learned from inﬂuenza vaccine introduction. He highlighted the gap in implementation
research, the need to optimize delivery strategies for vaccines in pregnancy, and the
importance placed on supporting such research as highlighted by WHO’s Strategic
Advisory Group of Experts (SAGE) in 2015. The progress, challenges, and opportunities
for maternal inﬂuenza immunization as identiﬁed by each of the WHO Regions were
then described. While in the African region (AFRO) competing infectious disease
priorities were of signiﬁcant concern, low population uptake in the European region
(EURO) was a particular challenge. Currently, the Panamerican Health Organization
(PAHO) is reported as the region making the strongest progress overall. Dr. Lambach
described the framework for introducing a new maternal vaccine into a country
program starting from the decision by policy makers and moving through the role of
those undertaking the implementation in planning the introduction, undertaking
training and ensuring effective communication, and subsequently monitoring and
evaluating the program. Finally, the “WHO Maternal Inﬂuenza Introduction Implemen-
tation Manual” was ﬁttingly launched on the day of the meeting (12 September 2017)
and was recommended to the audience as a source for Extended Program on Immu-
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nizations (EPI) managers and other interested parties planning such introductions (5).
(Guidance documents can be found at http://www.who.int/immunization/research/
development/inﬂuenza_maternal_immunization/en/index1.html.)
Edwin Asturias (University of Colorado, Denver, CO, USA) discussed the fact that the
integration of maternal and young infant immunization programs must address the
effects of both schedules on the safety, the immunogenicity, and the overall efﬁcacy of
the vaccines, as well as programmatic issues. An ideal schedule was considered to offer
the best opportunity to provide optimal protection with the minimum of risk. It was
highlighted that the 6-, 10-, and 14-week primary immunization schedule had been
adopted to maximize vaccine coverage in early infancy as rapidly as possible and had
been highly effective at preventing disease. However, in reality most infants receive
their vaccines at an average of 2.5, 4.5, and 8 months of age. The many factors affecting
an infant’s response to their primary series were listed, and Dr. Asturias reviewed a
number of the key publications demonstrating the effects of MatAbs, including breast
milk Abs, on infant vaccine immunogenicity (32–39). He also highlighted the growing
appreciation of the role of the microbiota in infant immunity (40, 41). He concluded that
true integration of maternal and infant immunization schedules might involve a delay
in the administration of those vaccine antigens against which the infant was effectively
protected by MatAbs until such Abs had waned sufﬁciently. This would also provide
greater opportunities for the later booster vaccinations required for long-term protec-
tion and, in many cases, indirect protection in the population.
Begoña Martinez de Tejada (University Hospitals of Geneva, Switzerland) presented
the results of two prospective, observational, nonrandomized studies comparing the
transfer of antipertussis Abs to the newborn following vaccination in the second
compared to the third trimester of pregnancy (25, 42). In both term and preterm
infants, second-trimester vaccination conferred higher Ab concentrations to the new-
born, and hence, a lower number of infants remained seronegative following second-
trimester vaccination. Dr. Martinez de Tejada concluded with a recommendation for
second-trimester pertussis vaccination.
Gayatri Amirthalingam (Public Health England, United Kingdom) discussed the
successes and challenges of the maternal pertussis immunization program in England.
The program was introduced in 2012 in response to a sharp increase in pertussis
disease cases in those too young to have been vaccinated (23). Although the program
was successfully implemented early on, coverage was increased when the start of the
window for vaccination was broadened from28 to16 weeks of gestation, based on
data from recent studies (as described by previous presenters). Over 90% vaccine
effectiveness has been demonstrated consistently since introduction (23). In the United
Kingdom, infant mortality from pertussis has substantially decreased since the intro-
duction of maternal Tdap vaccination, with no cases of death reported to date in infants
born to correctly vaccinated mothers (43). Dr. Amirthalingam also highlighted that any
effects of maternal antibodies (MatAbs) in infant immune responses have not thus far
translated into measurable impact on clinical disease in young children.
Sonali Kochhar (Global Healthcare Consulting, India) provided an overview of the
study design and regulatory and safety considerations for maternal immunization
clinical research in low- and middle-income countries. Beate Kampmann (Imperial
College of London, United Kingdom) introduced the recently formed “Immunizing
Pregnant Women and Infants” (IMPRINT) network, highlighting the purpose of the
network, which brings together multidisciplinary stakeholders in the ﬁeld to address
speciﬁc scientiﬁc challenges (http://www.imprint-network.co.uk/).
New and potential future targets for maternal and neonatal immunization. (i)
Monoclonal antibodies. James Crowe (Vanderbilt University, Nashville, TN, USA) sug-
gested that in the next 5 years, Abs will be the new tools for the prevention of infectious
diseases and rational, structure-based vaccine design will replace empirical antigen devel-
opment. Better understanding of the shared elements of the human immune system is key
to understanding the performance of vaccines and Abs. Although human genomes differ,
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he contends, Ab genes are much the same and the Abs we produce are very similar—thus,
the study of one persons responses can be generalized to others. Further, Ab technology
is mature, rapid, and affordable, and there is experience of safety with Ab administration,
which is conceptually much less complex than vaccines.
There are currently licensed prophylactic Abs for anthrax and RSV, and the pipeline
includes next-generation RSV, Clostridium difﬁcile, Pseudomonas aeruginosa, staphylo-
coccal toxin, and inﬂuenza virus Abs. The ﬁrst successful identiﬁcation of therapeutic
Abs was for Marburg virus, and there are ongoing studies for other hemorrhagic fevers
and ZIKV. Potential new targets include pandemic inﬂuenza (for elderly and infants),
seasonal inﬂuenza, ZIKV, GBS, pertussis, MRSA, nosocomial infections (e.g., Acinetobac-
ter sp.), others currently listed as WHO agents of concern (e.g., Rift Valley fever virus,
Lassa fever virus, Pan “ﬂavivirus”), MERS CoV, and therapeutic rabies virus.
Structure-based vaccines are another option for developing new vaccines. New
epitopes are the alternative way to identify new candidates instead of whole infectious
agents. The Human Immunome Project (http://www.humanvaccinesproject.org/work/
human-immunome-program/) aims to determine the sequence of every human Ab and
T cell receptor. The human immunome comprises the complete set of recombined
immune receptor (T and B cell receptor) genes and is much larger than the human
genome. The goals of the Human Immunome Project are to deﬁne the number of
sequences; stability of repertoires over time; proportion of shared immunome; effects
of age, race/ethnicity, gender, and geography; and effects of vaccination and diseases
on the immunome and to deﬁne its complete structure and functional catalogue. The
project will allow investigators to better proﬁle the response to vaccines, understand
the genetic features underlying variability in response, facilitate rational structure-
based design, and identify new Ab-based therapeutics.
(ii) Vaccines for malaria and enteric pathogens. Sophie Roetynk (MRCG at LSHTM,
The Gambia) presented the promising results of a randomized controlled trial on the
safety and immunogenicity of a malaria adenovirus-vectored vaccine (ChAd63/MVA
ME-TRAP) in infants and neonates. The vaccine was safe and well tolerated, resulting in
high-level immunogenicity, with the highest peak response observed in infants vacci-
nated at 8 weeks of age, and no interference with EPI vaccines (44). Esther Ndungo
(University of Maryland School of Medicine, USA) showed the results of a study
evaluating infant protection against shigellosis by naturally acquired and vaccine-
induced maternal immunity in a mouse model. Shigella is a primary cause of diarrhea
in children 5 years of age according to ﬁndings of the Global Enteric Multicenter
Study (GEMS). In a mouse model of maternal antibody (MatAb) transfer and challenge
study, Dr. Ndungo demonstrated that Shigella antigen-speciﬁc IgG and functional Abs
can be transferred to pups via placenta and milk of immune mothers, that maternal
vaccination (systemic IgG) protects infant mice against mucosal infection, and that
protection persists beyond weaning. A seroepidemiology cohort study in maternal-
infant pairs is being conducted in Malawi to evaluate the presence of invasion plasmid
antigen B (IpaB)- and lipopolysaccharide (LPS)-speciﬁc Abs in mothers, their transpla-
cental transfer to newborns, duration in infants, and correlation with protection.
(iii) Prevention of multidrug resistance to antibiotics. Ajoke Sobanjo-ter Meulen
(BMGF, USA) emphasized that globally, the neonatal mortality rate is declining more slowly
than the childhood mortality rate. She also noted growing numbers of facility-based births,
especially in India, with signiﬁcant implications for health care-associated neonatal infec-
tions. She showed data from the Delhi Neonatal Infection Study (DeNIS) collaboration from
3 hospitals in Delhi with high antimicrobial resistance rates among neonatal pathogens,
especially Gram-negative bacteria (45). Countries with the highest mortality rates also
demonstrate higher sepsis death rates as well as higher prematurity and intrapartum
stillbirth rates. These outcomes may reﬂect underlying infection, and evidence to support
this hypothesis exists from the CHAMPS study (https://champshealth.org). A recent review
has now estimated the burden of global deaths due to sepsis with antimicrobial-
resistant (AMR) organisms (46). Maternal vaccines (especially RSV and GBS) have the
potential to reduce AMR by reducing the empirical use of antibiotics. Regarding GBS
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strains, she mentioned rising rates of resistance to second-line antibiotics such as
macrolides and tetracycline. She noted the large number of women in high-income
countries who are receiving antibiotics in labor in order to prevent (early-onset) GBS
disease. Thus, effective vaccines could potentially reduce the numbers of infections,
reduce the need for antibiotics, reduce the emergence of resistant strains, and improve
prevention of resistant strains. Theoretically, a vaccine could be used to target deter-
minants of antibiotic resistance, and vaccines against important Gram-negative patho-
gens are already on the horizon (47). The development of monoclonal antibodies
(MAbs) at birth is also part of the Bill & Melinda Gates Foundation strategy, whereas
prophylactic MAbs could be given to infants determined to be at risk. MAbs may reduce
the need for or the duration of antibiotics. This approach could potentially be com-
bined with maternal immunization against the pathogens discussed above.
Panel discussions. The meeting concluded with two panel discussions. The ﬁrst
panel focused on the topic “Implementing and Integrating Maternal and Infant Immu-
nization: Challenges and Opportunities.” Participants were asked to address the follow-
ing key questions:
● What are the key challenges for the implementation of maternal immunization
programs worldwide?
● Is it feasible to, and what are the key challenges for integrating maternal and
infant immunization schedules?
● What are critical knowledge gaps that need to be addressed in order to ensure a
successful implementation of maternal immunization programs that complement
infant immunization programs?
● Based on your expertise, what are potential solutions to the challenges and
knowledge gaps you have identiﬁed?
The outcomes of this panel are described in Table 1.
In addition, the panel was asked if they considered it feasible to integrate maternal
and infant immunization schedules. The response was that in principle, this should be
feasible in many countries, taking into consideration the success of the maternal-
neonatal tetanus program. In order to achieve this, the panel suggested the following:
● Develop a maternal immunization investment case to depict the concept and
advantages of maternal immunization, using maternal tetanus vaccination as an
example (commonly appreciated in LMIC) and substantiated by sound country-
speciﬁc evidence on disease burden.
● Identiﬁcation of “champions” to push the maternal immunization agenda, espe-
cially regionally and at country level.
● Promotion of functional integration between EPI and Maternal Neonatal and Child
Health (MNCH) programs using all available means, with national governments
driving the process. Ideally equipping ANC clinics with immunization facilities—
logistics and skills.
● A strong maternal immunization platform is required that normalizes vaccination
practice among obstetric care providers and is supported by basic and continuing
education, communication strategy, and a broad range of research.
● Resource requirements’ implications, including human resources and funding,
should be adequately assessed and made available. Early and timely availability of
resources for program implementation and community awareness will be instru-
mental.
● Involvement of professional associations, such as of obstetricians and gynecolo-
gists and public health physicians with ongoing sensitization.
● Advocacy and capacity building; manufacturers and health care providers to be
explicit in providing safety information that speciﬁcally relates to product use in
pregnancy or neonates
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in
at
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n
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.
H
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y
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su
es
to
w
ar
d
im
m
un
iz
at
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n
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p
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gn
an
t
w
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en
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to
b
e
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es
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d
p
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tiv
el
y
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d
su
p
p
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te
d
b
y
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A
p
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t
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p
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ce
p
tio
ns
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p
re
gn
an
t
w
om
en
an
d
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m
m
un
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es
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ea
lt
h
ca
re
w
or
ke
r
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tit
ud
es
sh
ou
ld
b
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se
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.
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na
l
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un
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at
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m
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at
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n
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at
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d
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p
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p
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at
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p
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at
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im
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u
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at
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m
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n
t
im
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u
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iz
at
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le
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e
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l
b
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d
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s
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at
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p
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p
la
tf
or
m
s,
da
ta
co
lle
ct
io
n,
ge
ne
ra
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p
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b
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l
im
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at
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l
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m
m
un
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at
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p
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e
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e
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id
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gy
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m
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a
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st
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r
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y
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g
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e
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y
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e
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lo
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id
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ak
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de
r
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t
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y
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b
e
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ite
d.
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y
si
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iﬁ
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fe
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en
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fr
om
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y
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tt
in
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su
b
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ar
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A
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a
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a
fr
om
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m
p
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ep
id
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ca
l
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in
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n
b
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.
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fﬁ
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t
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ca
l
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l
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at
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an
d
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e
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b
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rm
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at
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p
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p
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at
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p
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l
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at
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b
y
p
re
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re
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op
m
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t
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l
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m
m
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at
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b
y
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p
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e
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at
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n
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an
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e
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I
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e
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b
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p
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e
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d
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I
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e
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in
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r
co
m
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at
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ra
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d
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ta
l
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an
d
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at
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n
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g
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b
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ve
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e
Be
rt
he
ls
(F
A
M
H
P,
Be
lg
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e
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b
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b
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at
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w
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p
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p
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in
g
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g
p
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al
th
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ni
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tio
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ul
at
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an
d
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et
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an
d
p
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tr
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al
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at
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p
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e
in
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n
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b
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r
C
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st
on
,T
X
,U
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b
re
vi
at
io
ns
:S
A
G
E,
St
ra
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c
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l
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at
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at
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b
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b
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e
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at
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at
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p
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ug
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at
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t
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an
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ve
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e
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p
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tin
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ct
m
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p
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y
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re
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b
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e
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at
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g
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re
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e
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e
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re
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e
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re
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p
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at
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b
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m
on
iz
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in
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ia
ls
an
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at
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b
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an
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p
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p
tio
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an
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e
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de
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p
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ve
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te
ra
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g
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b
e
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ng
th
en
ed
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e
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eq
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te
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p
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y
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d
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n
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y
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at
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r
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at
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p
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t
p
os
si
b
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ge
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er
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A
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Su
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p
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t
fo
r
re
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g
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ne
ed
ed
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r
b
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ic
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ie
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e
b
ut
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r
co
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io
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b
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el
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e
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l
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e
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to
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b
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at
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r
b
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ol
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st
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n
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en
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ge
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er
en
t
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m
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al
is
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m
in
g
of
va
cc
in
at
io
n
du
rin
g
p
re
gn
an
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m
e
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va
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in
at
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n
w
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de
te
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in
e
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p
ro
te
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e
an
tib
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y
at
th
e
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e
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en
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ur
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e
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ra
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n
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e
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e
w
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Im
p
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t
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va
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in
at
io
n
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Im
p
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t
of
no
ve
l
va
cc
in
es
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an
y
ex
is
tin
g
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cc
in
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al
re
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y
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th
e
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du
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ne
ed
s
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b
e
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ar
iﬁ
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o
in
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du
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g
an
d
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ea
lt
h
sy
st
em
s
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su
es
Lo
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st
ic
s
of
an
te
na
ta
l
ca
re
an
d
EP
I
M
at
er
na
l
va
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in
at
io
n
is
a
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ld
en
op
p
or
tu
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to
b
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g
A
N
C
an
d
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I
to
ge
th
er
.
Th
e
kn
ow
le
dg
e
of
fr
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t-
lin
e
he
al
th
ca
re
w
or
ke
rs
ad
m
in
is
te
rin
g
va
cc
in
es
ne
ed
s
to
im
p
ro
ve
th
ro
ug
h
ap
p
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p
ria
te
tr
ai
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ng
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A
n
in
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st
m
en
t
ca
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ne
ed
s
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b
e
m
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e,
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p
ol
ic
y
re
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te
s
to
co
st
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So
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ul
tu
ra
l
is
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es
O
p
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iz
in
g
sh
ar
in
g
of
kn
ow
le
dg
e
an
d
im
p
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m
en
ta
tio
n
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p
re
gn
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m
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se
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e
in
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rm
SA
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E
an
d
p
re
p
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e
ap
p
ro
p
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te
fo
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w
-u
p
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ud
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s
an
d
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y
im
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m
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at
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n
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b
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b
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at
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p
p
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p
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p
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re
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n
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b
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b
e
en
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.g
.,
la
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up
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m
m
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e
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d
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b
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un
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at
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n
p
la
tf
or
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b
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at
er
na
l
im
m
un
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at
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l
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at
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b
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at
io
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l
le
ar
ni
ng
b
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e
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at
er
na
l/
ne
on
at
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at
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b
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at
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b
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at
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b
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at
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b
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re
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p
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p
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b
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p
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The second panel discussion focused on identifying “Key Messages from Stakehold-
ers.” The panel members were chosen to represent the multiple disciplines relevant to
this ﬁeld. All panelists had prepared a statement summarizing 3 key challenges in their
area, and proposed solutions, which are summarized in Table 2.
Concluding remarks. Basic science is evolving quickly, providing new insights on
mechanisms of protection of mothers and young infants through maternal immuniza-
tion. Clear challenges and goals were formulated by participants at the meeting,
spanning basic sciences, clinical research, and implementation work; progress in all
areas is needed to enhance our knowledge about vaccines currently recommended for
maternal and neonatal immunization and neonatal immune development to derive
rational future targets for vaccination during pregnancy and early life. The meeting’s
deliberations actively contributed toward the goal of global implementation and
integration of maternal and infant vaccination strategies.
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